Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Neuilly-Sur-Seine – page 118

3 430 clinical trials in Neuilly-Sur-Seine, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Neuilly-Sur-Seine at a glance
3 430
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

3 430 trials in Neuilly-Sur-Seine

Open in trial search

Epidermolysis bullosa

Not yet recruiting

Assessing the efficacy and safety of nemolizumab in patients aged 12 years or older with dystrophic epidermolysis bullosa

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Centre Hospitalier Universitaire De Nice

Atrial fibrillation+1

Not yet recruiting

Landiolol hydrochloride to prevent new‑onset atrial fibrillation after heart surgery in Caucasian patients undergoing cardiopulmonary bypass

Registered drug
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Sodium Chloride
  • Sponsor:GCS Ramsay Sante Enseignement Et Recherche

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of epcoritamab, venetoclax and ibrutinib in treatment‑naïve chronic lymphocytic leukemia patients with TP53 alterations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:LYSARC

Sjogren's syndrome

Not yet recruiting

A Phase 2a/b Study of DDY391 to Evaluate Efficacy, Safety and Tolerability in Adults with Sjögren's Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer+1

Not yet recruiting

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Breast cancer+1

Not yet recruiting

Long‑term safety study of alpelisib alone or with fulvestrant in adults with breast cancer who benefited from previous alpelisib treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Adenocarcinoma pancreas

Not yet recruiting

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Mucormycosis

Not yet recruiting

Efficacy of isavuconazonium sulfate and amphotericin B drug combination for initial treatment of mucormycosis in adults

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amphotericin B
  • Sponsor:Assistance Publique Hopitaux De Paris

Phase II trial evaluating trastuzumab deruxtecan in patients with HER2‑positive advanced/metastatic cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Centre Leon Berard

Renal transplant

Not yet recruiting

Efficacy of daily high‑dose sulfamethoxazole‑trimethoprim prophylaxis versus low‑dose on bacterial infections in kidney transplant recipients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sulfamethoxazole
  • Sponsor:Assistance Publique Hopitaux De Paris

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Neuilly-Sur-Seine

What the registry says about research in the country

01 Gastrointestinal Research

Extensive clinical trials focusing on inflammatory bowel diseases, particularly investigating innovative treatments for Crohn's Disease and Ulcerative Colitis. Multiple studies are evaluating novel therapeutic approaches for patients with moderate to severe conditions.

  • Crohn's Disease Management
  • Ulcerative Colitis Treatments
  • Post-operative Care Studies

Research includes both induction and maintenance therapies, with emphasis on long-term patient outcomes.

02 Cardiovascular Studies

Innovative research in cardiac conditions, including studies on acute myocarditis treatment and prevention of post-operative complications. Trials are examining both therapeutic and preventive approaches.

  • Myocarditis Treatment
  • Post-operative Care
  • Cardiac Surgery Outcomes

Focus on improving patient outcomes through targeted interventions and innovative surgical techniques.

03 Oncology Research

Advanced studies in cancer treatment, including trials for head and neck squamous cell carcinoma and colorectal cancer. Research focuses on both targeted therapies and combination treatments.

  • Metastatic Cancer Treatment
  • Colorectal Cancer Management
  • Prostate Cancer Therapy

Emphasis on developing personalized treatment approaches and improving survival rates.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.